Drug and Alcohol The NSLHD Drug and Alcohol service has a strong focus on research. In 2020, the group delivered its first research strategy, which is aligned with the NSLHD Research Strategy 2019-2024, and demonstrates the value the group puts on supporting research. In the last three years, the number of research projects grew from one to 20 projects. The drug and alcohol group was also invited to join the NSW Ministry of Health-sponsored Drug and Alcohol Clinical Research and Improvement Network.
Publication highlights include: › Grebely J, Read P, Cunningham EB, et al. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial. Health Sci Rep. Jun 2020;3(2):e151. doi:10.1002/hsr2.151 › Kloft L, Otgaar H, Blokland A, et al. Cannabis increases susceptibility to false memory. Proc Natl Acad Sci U S A. Mar 3 2020;117(9):4585-4589. doi:10.1073/ pnas.1920162117 › Lintzeris N, Monds LA, Bravo M, et al. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. Drug Alcohol Rev. Jan 2020;39(1):55-65. doi:10.1111/dar.13015 › Mills L, Lintzeris N, Bruno R, et al. Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug Alcohol Rev. May 2020;39(4):356-364. doi:10.1111/dar.13050 › Valerio H, Alavi M, Silk D, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study. Clin Infect Dis. May 18 2020;doi:10.1093/cid/ciaa571
Key 2020 drug and alcohol research projects include: › Pilot study of an internet-based, simulated teachable moment for smoking cessation › Defining the clinical role of topiramate in the treatment of alcohol dependence in Australia › Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) › An open-label, multicentre, single-arm trial of monthly injections of extended release buprenorphine in people with opioid dependence (CoLAB Extension Study) › Examining clinical outcomes and quality indicators for clients attending NSW AOD treatment services Amphetamine Type Substances (ATS) group (Clinical Outcomes and Quality Indicators Cohort Study) › Obtaining normative substance use data for clients attending NSW public drug and alcohol treatment services (Clinical Outcomes and Quality Indicators Cohort Study). › NSW dried blood spot self-sampling HIV and
hepatitis C testing pilot program › Australian longitudinal study of heroin dependence
WWW.NSLHD.HEALTH.NSW.GOV.AU 19
Made with FlippingBook - professional solution for displaying marketing and sales documents online